Symposium
[Postponed] Preclinical and Clinical Development of Cell-based Immunotherapies: Translational PKPD, Safety, Biomarker, CMC, Clinical Pharmacology & Clinical Trials
Speakers:
Organizers:
Date:
2020-04-13- 04/13/2020
Time:
8:45-17:00 Pacific Time
Registration fee:
(USD):
Location:
Online
Major Sponsor:
Vendor show vendors registered to date:
(5)BioAgilytix Labs; ICON Clinical Research; PPD; SCIEX; Three Pillars Biotechnology Consulting
Registration: http://www.PBSS.org
Registration deadline:2020-10-19
(it will close sooner if the seating cap is reached)
About the Topic
The symposium will cover the preclinical and clinical strategies employed in the development of cell-based therapies. Topics include preclinical data package to support first in human studies, clinical pharmacology, design of early clinical trials, CMC considerations and regulatory expectations. The symposium will discuss the current strategies employed and address some of the challenges we face while advancing these therapies to patients. Additionally, topics such as biodistribution and “clearance” mechanisms, immunogenicity, translational PKPD, the relevance of preclinical models, projection of efficacious dose, etc will be addressed. Case studies will include development of CAR T-cells such as Kymriah® and Yescarta®.
--
Outcomes
- Understand factors that govern the biodistribution, clearance, and mechanism of action of cell-based therapies
- Develop a preclinical FiH package from a pharmacology/PKPD/tox/immunogenicity perspective
- Develop a Clinical Pharmacology Plan for cell therapies
- Understand clinical development and regulatory strategy for cell therapies
- Understand manufacturing processes and challenges
--
Agenda
8:45 am Welcome note and speaker introductions (Chunze Li, PhD, Director & Principal Scientist, Clinical Pharmacology; Vittal Shivva, PhD, Scientist, PKPD, Genentech)
Keynote Address
9:00 am Clinical Development of BCMA Targeted Immunotherapies in Multiple Myeloma (Kristen Hege, MD, Senior Vice President, Early Clinical Development, BMS)
Regulatory Perspective
9:45 am Regulatory Perspectives on cell therapy (Xiaofei Wang, PhD, Pharmacologist, FDA CBER)
10:15 am Break
Session 1: Introduction to Cell Therapy, Non-Clinical and Clinical Considerations
10:45 am A Research Perspective on Cell-based Immunotherapies: concepts, considerations and challenges (Sascha Rutz, PhD, Senior Scientist, Cancer Immunology, Genentech)
11:15 am PharmTox Considerations for Cell Therapy: A broad overview of the Pharmacology and Safety studies to support FIH study (Justine Cunningham, PhD, Vice President, Toxicology & Biodistribution, Sana Biotechnology)
11:45 pm Clinical Pharmacology Considerations for cell therapy (Weirong Wang, PhD, Scientific Director, Janssen R&D, J&J)
12:15 pm Lunch break
Session 2: Clinical Development and CMC Considerations
1:15 pm Clinical Development of Cell based Therapeutics (Yu-Waye (Wayne) Chu, MD, Senior Vice President, Fate Therapeutics)
2:00 pm CMC considerations for Cell Based Therapies: Controlling Living Drugs (Karen Walker, Senior Advisor, Cell and Gene Therapy Manufacturing, Genentech)
2:45 pm Break
Session 3: Case Studies
3:15 pm Clinical Pharmacology and Biomarkers Associated with Clinical Outcomes Supporting Approval of YESCARTA® (Vicki Plaks, LLB, PhD, Principal Scientist, Translational Medicine, Kite, A Gilead Company)
3:45 pm Biodistribution/Preclinical PKPD of Kymriah (Karen Thudium Mueller, PhD, Clinical Pharmacologist, Novartis)
Panel Discussion and Wrap-up
4:15 pm Panel Discussion (All Speakers) and Q&A (Moderator: Vittal Shivva, PhD, Scientist, PKPD, Genentech)
4:45 pm Wrap-up & Closing remarks (Amrita Kamath, PhD, Director & Principal Scientist, PKPD, Genentech)
2024-04-12, [Free Online] Innovative Life Science Technologies in the Drug Development Toolbox: From Cancer Organoids and Biomarker Profiling to Label-Free Multiplex QES Assays
|
2024-04-26, [In-Person] Oncology Clinical Dose Optimization in Light of FDA Project Optimus
|
2024-05-06, [In-Person] Human Mass Balance and Metabolite Profiling Studies: Strategies, Technical Approaches, Regulatory Guidance, Applications and Case Studies
|
2024-05-13, [Free Online] Highlights of 2023 FDA Drug Approvals
|
2024-05-21, [In-Person] Nonclinical Safety Studies for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-05-30, [Online Workshop] Career Transition for Research Scientists
|
2024-06-13, [In-Person] CMC Strategies and Activities for IND and NDA Filing for Small Molecules: Nuts, Bolts and Best Practices
|
2024-06-20, Alzheimer's Disease: untangling what we thought we knew and future Precision Medicine Diagnostics and Therapeutics
|
2024-09-10, [In-Person] Rethinking Translational PK/PD and Human Dose Projections for Novel Therapeutic Modalities: Covalent Inhibitors, PROTACs, Molecular Glues, ADCs, Ocular and Neuro delivery, Vaccines, Bispecifics, Cell and Gene Therapies
|
2024-09-20, [In-Person] Non-clinical safety assessments of biologics and novel modalities for IND/NDA Filing: Nuts, Bolts and Best Practices
|
2024-10-10, [In-Person] Regulatory Global Submission: Strategies and Best Practices for FDA, EMA and PMDA
|